|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
WO1993004169A1
(en)
|
1991-08-20 |
1993-03-04 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
ATE347593T1
(de)
|
2002-01-23 |
2006-12-15 |
Univ Utah Res Found |
Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
|
|
EP1504092B2
(en)
|
2002-03-21 |
2014-06-25 |
Sangamo BioSciences, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
US9447434B2
(en)
|
2002-09-05 |
2016-09-20 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
KR20070060115A
(ko)
|
2004-09-16 |
2007-06-12 |
상가모 바이오사이언스 인코포레이티드 |
단백질 생산을 위한 조성물 및 방법
|
|
EP2027262B1
(en)
|
2006-05-25 |
2010-03-31 |
Sangamo Biosciences Inc. |
Variant foki cleavage half-domains
|
|
US7951925B2
(en)
|
2006-05-25 |
2011-05-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene inactivation
|
|
US8110379B2
(en)
|
2007-04-26 |
2012-02-07 |
Sangamo Biosciences, Inc. |
Targeted integration into the PPP1R12C locus
|
|
CA2720903C
(en)
|
2008-04-14 |
2019-01-15 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
JP5908725B2
(ja)
|
2008-08-22 |
2016-04-26 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
標的一本鎖開裂および標的組込みのための方法、並びに組成物
|
|
EP3156494B8
(en)
|
2008-12-04 |
2018-09-19 |
Sangamo Therapeutics, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
US9255259B2
(en)
|
2010-02-09 |
2016-02-09 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
AU2011256838B2
(en)
|
2010-05-17 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Novel DNA-binding proteins and uses thereof
|
|
EP2758529B1
(en)
|
2011-09-21 |
2019-03-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
|
US9222105B2
(en)
|
2011-10-27 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
|
SG10201704846VA
(en)
|
2012-03-14 |
2017-07-28 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
WO2013141680A1
(en)
|
2012-03-20 |
2013-09-26 |
Vilnius University |
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
EP4397759A3
(en)
|
2012-10-23 |
2024-10-09 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
DK3363902T3
(da)
|
2012-12-06 |
2020-01-02 |
Sigma Aldrich Co Llc |
Crispr-baseret genommodifikation og -regulering
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
IL308158A
(en)
|
2012-12-17 |
2023-12-01 |
Harvard College |
Rna-guided human genome engineering
|
|
WO2014131833A1
(en)
|
2013-02-27 |
2014-09-04 |
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Gene editing in the oocyte by cas9 nucleases
|
|
ES2887254T3
(es)
|
2013-03-08 |
2021-12-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para el suministro de agentes activos
|
|
CN105408483A
(zh)
|
2013-03-15 |
2016-03-16 |
通用医疗公司 |
遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
|
|
EP4286517A3
(en)
|
2013-04-04 |
2024-03-13 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
EP3058072B1
(en)
|
2013-10-17 |
2021-05-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
EP3110454B1
(en)
|
2014-02-24 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
AU2015277369B2
(en)
|
2014-06-16 |
2021-08-19 |
The Johns Hopkins University |
Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
|
|
WO2015200555A2
(en)
|
2014-06-25 |
2015-12-30 |
Caribou Biosciences, Inc. |
Rna modification to engineer cas9 activity
|
|
CN106794141B
(zh)
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
CN113337533A
(zh)
|
2014-12-23 |
2021-09-03 |
先正达参股股份有限公司 |
用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
JP6851319B2
(ja)
*
|
2015-04-27 |
2021-03-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ヒト疾患のCRISPR/Cas9媒介性の修正のためのデュアルAAVベクター系
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
US11279928B2
(en)
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
JP6993958B2
(ja)
|
2015-07-06 |
2022-02-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性抗原結合分子およびその使用
|
|
MY207684A
(en)
|
2015-12-08 |
2025-03-12 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
ES3030658T3
(en)
|
2016-03-30 |
2025-07-01 |
Intellia Therapeutics Inc |
Lipid nanoparticle formulations for crispr/cas components
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
KR102617502B1
(ko)
*
|
2016-09-12 |
2023-12-26 |
제네똥 |
산-알파 글루코시다제 변이체 및 이의 용도
|
|
EP3551757A1
(en)
|
2016-12-08 |
2019-10-16 |
Intellia Therapeutics, Inc. |
Modified guide rnas
|
|
AU2018281280B2
(en)
|
2017-06-07 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
IL311278B2
(en)
|
2017-09-29 |
2026-05-01 |
Intellia Therapeutics Inc |
Polynucleotides, compositions, and methods for genome editing
|
|
EP3688162B1
(en)
|
2017-09-29 |
2024-03-06 |
Intellia Therapeutics, Inc. |
Formulations
|
|
CN111683972A
(zh)
*
|
2018-02-05 |
2020-09-18 |
Jcr制药股份有限公司 |
用于将药剂递送至肌肉的方法
|
|
CN112040985A
(zh)
*
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
|
SG11202011191WA
(en)
*
|
2018-05-16 |
2020-12-30 |
Spark Therapeutics Inc |
Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
|
|
EP3793591A1
(en)
*
|
2018-05-17 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
BR112021005718A2
(pt)
|
2018-09-28 |
2021-06-22 |
Intellia Therapeutics, Inc. |
composições e métodos para edição de genes de lactato desidrogenase (ldha)
|
|
CN113272428A
(zh)
|
2018-10-18 |
2021-08-17 |
英特利亚治疗股份有限公司 |
核酸构建体和使用方法
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス,インコーポレーテッド |
第ix因子を発現するための組成物及び方法
|
|
BR112021007343A2
(pt)
|
2018-10-18 |
2021-08-03 |
Intellia Therapeutics, Inc. |
composições e métodos para expressão de transgene a partir de um lócus de albumina
|
|
WO2020102645A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus for treating pompe disease
|